SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SSgA Active Trust - SPDR S&P 500 ETF Trust

Renewed tariff threats against European allies, stemming from the Greenland situation, are currently dominating market discourse for SPY and impacting futures. While some investors anticipate a significant market pullback, many view any dip as a familiar "buy the dip" opportunity, expecting a rapid recovery as markets have previously navigated similar geopolitical "drama". The community is actively debating the potential for broader trade implications and forthcoming economic and political developments to shape near-term direction.

Invesco Capital Management LLC - Invesco QQQ Trust Series 1

QQQ is trending as renewed tariff threats regarding Greenland trigger market volatility, with the community sharply divided between those anticipating a significant correction and "buy the dip" proponents. Investors are weighing escalating geopolitical tensions and rising treasury yields against historical market resilience and expectations for a robust tech earnings season.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Shares of Trump Media & Technology Group are trending as recent statements from Donald Trump regarding Greenland's acquisition and associated tariff threats on European nations spark intense debate. The community is actively discussing the geopolitical implications and potential market volatility, with sentiment largely driven by reactions to these prominent political headlines.

AppLovin Corp. engages in the development and operation of a mobile marketing platform. It offers AppDiscovery, MAX, Adjust, and SparkLabs. Its software-based platform caters to mobile application developers to improve the marketing and monetization of applications. The company was founded by Andrew Karam, John Krystynak, and Adam Foroughi in 2011 and is headquartered in Palo Alto, CA.

Applovin Corp - Ordinary Shares - Class A

Applovin Corp

Applovin (APP) is experiencing significant recent volatility and a notable pullback, sparking intense community debate. While bulls highlight strong fundamental growth from its AI-powered AXON platform and recent analyst upgrades as a "buy the dip" opportunity, bears point to circulating short report rumors and broader ad-tech sector weakness, alongside discussions of options market dynamics, as reasons for the sharp decline. This creates a highly active discussion about the stock's near-term direction ahead of upcoming earnings.

Volatility Shares Trust - 2x Long VIX Futures ETF

Volatility Shares 2x Long VIX Futures ETF

Volatility Shares 2x Long VIX Futures ETF (UVIX) is seeing intense discussion as escalating geopolitical tensions, from US actions in Venezuela and Greenland to EU tariff disputes and potential escalations with Iran and China, fuel expectations for a market-wide fear spike. Traders are actively positioning for a major upward move in volatility, leveraging UVIX for short-term hedges while widely acknowledging its pronounced decay characteristics make it unsuitable for extended holding.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio (IBRX) is trending with high investor enthusiasm following international approvals for its Anktiva treatment in both lung and bladder cancers, notably a first-in-world non-chemo combo for lung cancer from Saudi Arabia. This significant progress, coupled with reported substantial revenue growth, is generating widespread community discussion about the company's transformative potential in oncology and fueling considerable short squeeze speculation due to high short interest. Investors are closely monitoring further global regulatory developments and anticipating a paradigm shift in cancer treatment as Dr. Patrick Soon-Shiong actively promotes the company's innovative "BioShield" platform.

Cadrenal Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in developing novel therapy. It develops tecarfarin, a novel therapy with orphan drug indication, designed for the prevention of systemic thromboembolism of cardiac origin in patients with end-stage renal disease and atrial fibrillation. The company was founded by Quang X. Pham and Matthew K. Szot on January 25, 2022 and is headquartered in Ponte Vedra, FL.

Cadrenal Therapeutics Inc

Cadrenal Therapeutics, Inc.

Cadrenal Therapeutics is drawing attention following recent developments in its pipeline, including the acquisition of VLX-1005 and ongoing progress for its lead anticoagulant, tecarfarin, notably through a collaboration with Abbott for pivotal trials. Community discussion is split between excitement over its potential in treating rare cardiovascular conditions and concerns regarding dilution and the need for substantial financing for upcoming clinical milestones. Its ultra-low float is also a key talking point, contributing to observed volatility and the potential for significant price action.

The Mullen Army Token originated from a dedicated community of retail investors who faced challenges in the traditional stock market. We united to create a cryptocurrency that embodies our principles and aspirations for a fair financial system.     We provide a platform for retail investors to engage in a transparent and fair financial market. Our efforts include grassroots marketing, community engagement, and educational content to empower our investors.

MullenArmy

MULN CRYPTO is trending due to a mix of strong skepticism and active promotion, with many users questioning its legitimacy and connection to the controversial Mullen Automotive stock, often cited as a past "scam." While some in the community label it "garbage" and warn of further losses, a dedicated segment is actively calling for accumulation and anticipating significant price surges for the "Mullen Army" token on the Solana network.

ProShares Trust - ProShares VIX Short-Term Futures ETF

ProShares VIX Short-Term Futures ETF

ProShares VIX Short-Term Futures ETF ($VIXY) is trending as renewed discussions around escalating geopolitical tensions, potential government actions like tariffs, and broader market overvaluation fuel expectations for increased volatility. The community is actively debating whether current market conditions warrant a substantial spike in volatility, with many viewing $VIXY as a critical hedge against potential market shifts.

ProShares Trust - ProShares Ultra Bloomberg Natural Gas 2x Shares

ProShares Ultra Bloomberg Natural Gas

Natural Gas prices are surging dramatically, driven by widespread forecasts for an intense Arctic blast across the US, with many in the community anticipating a significant short squeeze and a substantial gap-up for BOIL when markets open. Traders are actively debating whether these substantial gains will hold, given the highly volatile nature of leveraged natural gas ETFs like BOIL.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Retail chatter around Cingulate picked up on Tuesday after Roth Capital Partners raised its price target to $17 from $10 and reaffirmed a ‘Buy’ rating.&nbsp;<a href="https://stocktwits.com/symbol/CING">Cingulate Inc.’s stock</a> snapped a two-day losing streak, rising 2.5% to $4.15 on Tuesday, and added another 1.6% in after-hours trading.The firm said the FDA’s acceptance of Cingulate’s application for its ADHD drug CTx-1301 signals confidence in the treatment’s safety and effectiveness for both children and adults.Roth analysts said the absence of an Advisory Committee review, an earlier-than-expected PDUFA date of May 31, 2026, and a potentially broad label across ADHD patients all strengthen the investment case for Cingulate. They also highlighted the strong approval track record of ADHD stimulants as supportive of the drug’s prospects.The FDA’s acceptance marks a major step forward for CTx-1301, which uses Cingulate’s proprietary Precision Timed Release technology to deliver once-daily, all-day symptom control. The company said Phase 3 data showed rapid onset and sustained efficacy with no serious safety issues reported.The company called the FDA acceptance a “defining milestone”, positioning Cingulate to transition from a development-stage to a commercial-stage company in 2026, pending approval. The firm said commercial preparations are already underway through partnerships with Bend Bio Sciences and Indegene to ensure manufacturing scale-up and market readiness.On Stocktwits, retail sentiment for Cingulate was ‘bullish’ amid an 820% surge in 24-hour message volume.One bullish user highlighted the advantages of Cingulate’s regulatory route, noting it follows a faster and less expensive path typically used for drugs that build on existing approvals with new delivery methods. They noted the company’s silence on social media could hint at buyout interest and said they would only part with their shares for $27.<stembedurl>https://stocktwits.com/StockGuru320/message/632269303</stembedurl>Another bullish user noted that, with the NDA now accepted, the real question for investors was the risk they were taking by not owning the stock at this stage. They added that long-term holders were feeling more confident than ever about the company’s direction.<stembedurl>https://stocktwits.com/Duke1979/message/632260917</stembedurl>Cingulate’s stock has declined 16% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Cingulate’s stock (CING) has declined 16% so far in 2025. (Photo credit: Getty Images)

Cingulate Stock Snaps 2-Day Losing Streak As Roth Hikes Target On ADHD Drug Review; Retail Bets On Buyout Potential

Roth Capital said the FDA’s acceptance shows strong confidence in Cingulate’s ADHD drug, adding that its early PDUFA date and clean regulatory path make it a good investment.

Equity

Retail chatter around Cingulate spiked Tuesday after Phase 3 data confirmed that its lead candidate, CTx-1301, significantly improved ADHD symptoms in pediatric patients within five weeks of treatment.At Tuesday's close, Cingulate shares fell 4.99% to $3.62 and slipped further 1.66% to $3.56 in after-hours trading.According to the Kansas-based biotech, children who took CTx-1301 at doses of 18.75 mg, 25 mg, and 37.5 mg experienced significant reductions in their ADHD-RS-5 scores.Dr. Raul Silva, chief science officer at Cingulate, revealed the possibility of CTx-1301 becoming a primary treatment option for ADHD after demonstrating effect sizes between 0.737 and 1.185, which surpass the industry standard of 0.73 for long-duration stimulants.CEO Shane Schaffer identified the findings as a “significant value inflection point” while confirming that the company plans to file a New Drug Application (NDA) this summer.CTx-1301 uses Cingulate’s Precision Timed Release platform to provide a single daily dose, which begins working in the morning and maintains effectiveness throughout the day.After receiving FDA approval, the company plans to offer eight different dosage strengths to address the pediatric and adult ADHD markets.On Stocktwits, retail sentiment was ‘extremely bullish’ amid a 2,700% surge in 24-hour message volume.One user highlighted the forthcoming FDA submission as a key milestone and suggested that the recent decline in share price may offer a buying opportunity.&nbsp;<stembedurl>https://stocktwits.com/Duke1979/message/615297512</stembedurl>Another user was more cautious, noting that the effect size observed in the pediatric trial appeared lower than earlier projections. However, they acknowledged that sustained efficacy throughout the day could remain a key differentiator.<stembedurl>https://stocktwits.com/TheSterl/message/615215732</stembedurl>The stock has declined 29% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Cingulate Retail Buzz Surges As ADHD Drug Shows Phase 3 Pediatric Efficacy

Phase 3 data showed the company’s ADHD drug, CTx-1301, significantly improved symptoms in children within five weeks. The company plans to file for FDA approval this summer.

Cingulate Inc.'s shares generated heightened retail chatter on Wednesday after receiving the FDA's pre-New Drug Application (NDA) meeting minutes for its primary asset CTx-1301 that targets ADHD with a daily stimulant treatment.Cingulate shares rose 8.7% to close at $4.25 on Tuesday but slipped 4.2% to $4.07 in after-hours trading.Following a pre-NDA meeting on April 2, the company confirmed that it will submit an NDA for CTx-1301 in the summer of 2025 based on the FDA’s feedback.&nbsp;The formulation CTx-1301 contains dexmethylphenidate and employs Cingulate’s Precision Timed Release technology to provide three doses during specific times of the day.&nbsp;The technology aims to overcome the problem of reduced effectiveness in existing stimulant treatments during the afternoon hours.The FDA minutes confirmed that the existing nonclinical safety data sufficiently support the NDA submission.The agency entered into a post-approval agreement with Cingulate to gather stability data for six intermediate dose strengths, spanning from 12.5 mg to 43.75 mg.The regulatory body recognized a scientific connection to Focalin XR, which permitted Cingulate to benefit from existing data on drug effectiveness and safety.&nbsp;The agency found the company’s integrated safety and efficacy summary approaches reasonable.One user said the stock could reach $6, citing a sharp spike to $5.16 as a signal of potential upward momentum.&nbsp;On Stocktwits, retail sentiment was ‘bullish’ amid a 1,600% surge in 24-hour message volume.<stembedurl>https://stocktwits.com/doublenickels55/message/614579894</stembedurl>Another user highlighted the absence of negative news and reaffirmed confidence in the NDA timeline, noting the company remains on track for a summer submission.<stembedurl>https://stocktwits.com/fullobullz/message/614577626</stembedurl>The stock has declined 16.7% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Cingulate Retail Buzz Rises After FDA Greenlights Summer NDA Filing For ADHD Drug

CTx-1301 employs its Precision Timed Release system to administer three doses of dexmethylphenidate throughout the day for managing ADHD symptoms.

<a href="https://stocktwits.com/symbol/CING">Cingulate Inc</a>. (CING) shares skyrocketed over 85% in pre-market trading on Friday, becoming the top trending stock on Stocktwits. The surge comes after the stock rallied nearly 160% on Thursday, triggered by the company's announcement of a European patent for its ADHD drug candidate, CTx-1301.This patent expands Cingulate's intellectual property protection to include up to 30 European countries, adding to its existing patents in Australia, Canada, and Israel. The company is also pursuing patents in Hong Kong, South Korea, and the United States.ADHD is a significant global health issue, affecting millions worldwide. Cingulate's focus on developing treatments for ADHD aligns with its broader strategy of utilizing its proprietary PTR technology for other therapeutic areas, such as anxiety disorders.The patent news has injected a much-needed dose of optimism into the stock, which has lost over 94% of its value this year due to several headwinds.The company reported disappointing Q2 earnings and has been grappling with financial challenges, including a significant cash burn and a history of top executive departures.Cingulate has a cash balance of just $0.4 million as of June 30, 2024. To address this, the company raised $1.6 million in July through warrant inducement and plans to seek additional funding.A regulatory filing last year warned of potential bankruptcy if financial issues persisted.<stembedurl>https://stocktwits.com/SelectiveTrader/message/583139933</stembedurl>Despite these challenges, the European patent news has reignited interest in Cingulate. However, it remains to be seen if this momentum can be sustained and if the company can successfully navigate its financial hurdles to capitalize on its drug development pipeline. &nbsp;

ADHD is a significant global health issue, affecting millions worldwide. Image via Vecteezy

Cingulate Stock Is Hottest Talk Of Retail Street After Europe Patent For ADHD Drug Candidate

Retail investors, buoyed by the news, are actively discussing the stock on Stocktwits. However, some remain cautious due to the company's troubled history and ongoing financial challenges.

Cingulate, Inc. operates as a clinical stage bio pharmaceutical company using a Precision Timed Release drug delivery platform technology to build a pipeline of next-generation pharmaceutical products. The firm initially focused on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD). It identifies and evaluates additional therapeutic areas, PTR technology employed to develop future product candidates. Cingulate was founded by Shane J. Schaffer, Craig Steven Gilgallon, Raul R. Silva, Matthew N. Brams in May 2012 and is headquartered in Kansas City, KS.

CING
Cingulate Inc

Feed

News

Sentiment

Fundamentals

Info

Latest CING News

CINGCingulate Inc